Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- Chuikyo Discussing Measures to Promote Proper Use of Clozaril for Patients with Treatment-Resistant Schizophrenia
October 19, 2017
- National Database Initiative for Regenerative Medicine Goes Live; Use for Review, Development Eyed
October 18, 2017
- Label Revisions Ordered for 5 APIs, Hitting Slew of Amoxicillin/Chlorhexidine Products
October 18, 2017
- Post-Transplant Patients Added to Careful Use List for Keytruda Label/Guidelines
October 18, 2017
- MHLW to Issue Notification on Revised Format for Package Inserts of Vaccines in Early December
October 18, 2017
- Cabinet Secretariat to Discuss Details of Research on Genome Editing to Be Supported by AMED
October 16, 2017
- MHLW to Purchase Enough Avigan for 44,000 More People, Agreement Expected Nov. 1
October 13, 2017
- Pricing Predictability Could Crumble via Japanese CEA Introduction, Tada Frets at Chuikyo
October 12, 2017
- Premium Rate Threshold Could Preclude CEA-Based Price Raise for Inapplicable Products: Chuikyo Doctor Rep
October 12, 2017
- FPMAJ Chief Trades Barbs with Chuikyo Payer Rep, Says Western-Style HTA Doesn’t Fit Japan’s Unique Market Mechanism
October 12, 2017
- Claims to ADR Victims Relief System Up 277 in FY2016: MHLW
October 12, 2017
- Any CEA-Based Price Adjustment Must Be Limited to Premium Rates: 3 Pharma Groups
October 11, 2017
- MHLW to Issue Basic Guide to PMS for Conditional Early Approval: Drug Review Chief
October 11, 2017
- Japan Needs “Quick and Low-Cost” R&D Setup: Top MD Bureaucrat
October 10, 2017
- MHLW’s JETRO NY Post Ended Because There Was No Request: Govt
October 10, 2017
- Health Minister Questions How to Gauge Success in Outcome-Based CAR-T Pricing in Japan
October 10, 2017
- Revised Ministerial Ordinance on Preventing Distribution of Counterfeit Drugs to Take Effect Jan. 31
October 10, 2017
- 3rd Round of Sakigake Invitations Begin
October 6, 2017
- Social Security Council Members Reiterate Opposition to Reference Pricing for LLPs, or LLP-Gx Uniform Prices
October 6, 2017
- MHLW to Place Priority on “Mutual Understanding” with Industry: Economic Affairs Chief
October 6, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…